Rating: Neutral | Target Price Range: HKD 0.20–0.30 (fair under the base case) | Current Price: HKD 0.196 (close on 2026-11-06) | Margin of Safety: approx. +2% (based on the lower bound of the base-case range at HKD 0.20) Time Horizon: 6–12 months | Market Cap: approx. HKD 230 million (total shares 1,171,854,481, per the 2026-10-31 monthly return) | Report Date: 2026-11-07 FX basis: RMB 1 = HKD 1.176071 (2026-11-07); financial data are in RMB, market data in HKD.
Hongguang Semiconductor is a micro-cap listed on the Main Board (formerly Hongguang Lighting; LED lamp bead business plus transformation into a GaN power semiconductor IDM via Shenzhen Jiahong, in which it holds roughly 68–73%). It currently exhibits a rare standoff structure of "asset discount vs. dilution-driven survival": the current price of HKD 0.196 implies P/B of approx. 0.46 (book value per share approx. HKD 0.42, lowest percentile of the past year); Chizhou SOE's RMB 80 million capital injection sets a post-money valuation of approx. RMB 1.158 billion for Shenzhen Jiahong, whose 68.21% stake held by the company is worth approx. HKD 930 million — about 4x the entire company's market cap. On the other side: the parent's cash is only approx. RMB 7.2 million, with a runway of approx. 2.5 months; the injection proceeds are locked for the Chizhou project and cannot rescue the parent; over the next 12 months, announcement-verifiable dilution in the pipeline is approx. 177 million shares (15.1%); family-related-party transaction chains and "equity in name, debt in substance" put-back clauses constitute continuous value leakage. Overall judgment: valuation is reasonably low, rating Neutral — base-case fair value of HKD 0.20–0.30 implies approx. +2% to +53% versus the current price; positive expected value is driven mainly by tail scenarios. The Chizhou injection's approval (circular to be dispatched no later than 2026-11-26) is the only high-grade catalyst in the next 6 months, but until it closes and the market gives positive feedback, liquidity and governance discounts are sufficient to block the conversion from "cheap" to "worth buying." The stock is suitable only for small-position, event-driven participation; not suitable for fundamental portfolio allocation.
The two major entities on the balance sheet (VisIC stake of RMB 155 million + book value of approx. RMB 114 million for the 68.21% Jiahong stake) together account for approx. 64% of equity attributable to shareholders. Applying a deep-discount SOTP — VisIC at 40–55% of book, Jiahong at 45–60% of book, LED at 25–40% of book, less net debt (approx. RMB 48.5 million at 2026-06-30; approx. RMB 26.9 million after the note swap) — yields an asset value range of approx. HKD 0.10–0.19/share: the optimistic end is already close to the current price, the pessimistic end implies approx. -49%. It must be emphasized that this range has no cash-out mechanism — the company has no dividend or buyback capacity (consecutive losses, cash of RMB 7.2 million); the Jiahong stake cannot be monetized before the qualified-listing window opens in 2031–2032; VisIC is a Level 3 asset whose book value is paper wealth for a holder at HKD 0.196. It is a valuation reference for the bear scenario, not a support level one can bank.
If the transaction closes, Jiahong gains an external pricing reference of approx. RMB 1.158 billion post-money; the company's 68.21% stake is worth approx. HKD 930 million (4.0x market cap), and for the first time "submission of a qualified listing application before 2031-12-31" is written into a contract. But three things must all hold for this to be a true anchor: first, the pricing is hybrid equity-debt — 6% simple-interest put-back + liquidation preference + anti-dilution + most-favored-nation treatment, with the repurchase obligor being a wholly-owned SPV of the Group and guaranteed by the Target Company; RMB 1.158 billion is closer to "a conversion price embedded with a 6% guaranteed return." Second, the anchor has a history of downward revision — in September 2023, Taizhou Huirong's RMB 100 million injection implied unit pricing of approx. RMB 108.7 per USD 1 of registered capital; Chizhou's approx. RMB 59.8 this time represents a near halving of unit pricing in three years. Third, the conditions precedent require the company to complete the approx. RMB 29 million MOCVD purchase before the investor's payment (approx. 4x the Group's cash at 2026-06-30), plus a self-funded RMB 20 million contribution before 2027-12-31 (breach triggers the put-back). In the 8 trading days after the announcement, the share price fell rather than rose, to the edge of its 52-week low — the market has yet to offer any "ratification" evidence.
The parent's average monthly cash burn is approx. RMB 2.9–3.0 million (2026H1 basis), a runway of approx. 2.5 months; bank borrowings doubled from RMB 10 million to RMB 20 million within six months, with a first-time charge over properties and equipment with a book value of RMB 43.1 million. Announcement-verifiable dilution in the pipeline: 115.5 million consideration shares + 61.54 million CB conversion shares = approx. 177 million shares (15.1% of current share capital); in addition, the 2023 share award scheme has approx. 93.88 million shares authorized but unissued (potential supply, not certain issuance). Historically, placement prices traced 6.20→3.20→0.90→0.80→0.48 HKD, all at discounts — but the 2026-11-06 prices of 0.22/0.26 HKD were premium issuances. Two pricing precedents exist for the next financing; the base case assumes issuance in the HKD 0.20–0.26 range; a deep-discount placement below HKD 0.15 would put the stock directly on the bear-case path.
Both sides must be stated: the direction of this related-party acquisition was not a one-way transfer of value — insiders sold Jiahong equity at an HKD 880 million valuation, and nine months later the SOE invested at an equivalent of approx. HKD 1.36 billion; with hindsight, insiders were the "sell-low" side. The 2026-11-06 note settlement replaced 2% notes with stock priced 12%–33% at a premium plus low-interest long-term debt — a dilution cost lower than a hypothetical issuance at market prices. But the "dual-track" fact stands: insiders exchanged subsidiary equity for listed stock consideration worth approx. 5.3x book, and their 146.8 million shares at a cost of HKD 0.50 constitute potential supply, while all shareholders bore the RMB 101 million equity write-off; the two family groups' combined stakes approach 44%, and independent shareholders have limited effective veto power over capital operations (related shareholders must abstain only on the connected transactions themselves). Whether the HKD 0.50 issuance price for the December 2025 acquisition represented a premium or discount to the then-market price has not been verified; judgment on the ultimate direction of value transfer is reserved.
The company's own GaN products are not on Nvidia's 800V HVDC supplier list (the sole Chinese entrant being Innoscience); the AI data-center inflection dividend is being captured by leading IDMs; indirect exposure is only via the approx. 18% stake in VisIC (whose D³GaN platform covers 400V/800V automotive and is extending to 800V data-center power). On the LED side, 2026H1 revenue rose 85.8% (volume and price both up; the company claims to be "outperforming industry trends"), but the price hike is cost-push and segment gross margin actually fell 3.9 percentage points — proof that the hikes have not yet translated into profit. With overall gross margin at 5.4%, turning profitable for the full year would require gross margin recovery above 15% or revenue more than doubling; the realistic path is "revenue growth + continued loss narrowing."
| Metric (RMB million) | FY2023 | FY2024 | FY2025 | 2026H1 (latest period, as of 2026-06-30) |
|---|---|---|---|---|
| Revenue | 88.6 | 75.3 | 97.8 | 51.6 |
| Revenue YoY | +1.2% | -15.0% | +29.9% | +55.9% |
| Net profit attributable to shareholders | -150.7 | -156.8 | -112.9 | -34.6 |
| Recurring net loss (our estimate, excluding one-off impairments/disposals/subsidies) | -96.7 | -112.8 | -110.6 | — (not recalculated item by item; share-based compensation was zero this period, amount close to reported loss) |
| Gross margin | 9.6% | 10.3% | 4.5% | 5.4% |
| Net margin | -170% | -208% | -115% | -67% |
| Operating cash flow | -23.2 | -69.7 | -28.9 | -13.9 |
| Free cash flow | -131.2 | -82.7 | -73.9 | -17.6 |
| Cash and equivalents (period-end) | 49.3 | 8.8 | 14.6 | 7.2 (of which 5.3 is RMB balances; for the non-freely-remittable portion see note) |
| Interest-bearing debt (period-end) | 10.0 | 10.0 | 10.0 | 55.7 (bank borrowings 20.0 + promissory notes 35.7; plus lease liabilities of 6.1) |
| Gearing (debt/equity, company basis) | — | 1.7% | 2.0% | 13.0% |
Notes: ① Metrics such as net debt/EBITDA and forward P/E are structurally distorted given negative EBITDA and earnings and are omitted; ② FY2023 capex (RMB 108 million) is an anchored figure from third-party market data sources (the results announcement for that period did not disclose investing cash flow details); all other figures are from company announcements; ③ The net cash basis is consistent across both periods (cash and cash equivalents, no restricted cash line item; Note 15 at 2026-06-30 discloses that RMB balances of RMB 5.287 million therein are not freely remittable).
Reasons for metric changes (items with YoY ≥ ±20%, all with management explanations): FY2024 expected credit loss provisions rose from RMB 1.325 million to RMB 42.918 million ("primarily due to the provision made on the remaining investment amount in Shenzhen Jiahong" — the Taizhou investor's second tranche of RMB 45 million defaulted); FY2024 share-based payment expenses rose from RMB 3.849 million to RMB 35.325 million (employee share award scheme); FY2025 revenue +29.9% ("primarily due to the increase in revenue from sales of GaN and other semiconductor products," GaN rising from RMB 1.36 million to RMB 29.59 million); FY2025 gross margin 10.3%→4.5% ("decline in average selling prices of LED lamp beads and increase in material costs, in particular gold wire"); 2026H1 LED revenue +85.8% ("steady demand in the high-value consumer electronics segment... average selling prices and total sales volume growing in tandem"); 2026H1 GaN revenue -34.8% ("large GaN manufacturers being at a competitive disadvantage in pricing"); 2026H1 administrative expenses -40.3% (share-based payments from RMB 20.79 million to zero, R&D from RMB 23.5 million to RMB 17.5 million); 2026H1 interest-bearing debt 10.0→55.7 million RMB (bank borrowings doubled, secured by RMB 43.1 million of properties and equipment, plus new promissory notes).
2026H1 revenue was RMB 51.62 million, +55.9% YoY — the strongest half-year growth in four years; loss attributable to shareholders was RMB 34.64 million, narrowed 41.6% YoY (prior-year period: -59.29 million). Decomposition of the improvement: the LED segment's revenue of RMB 46.32 million (+85.8%) contributed the entire increment, which management attributed to high-value consumer electronics demand and gains in both volume and price; GaN segment revenue was RMB 5.30 million (-34.8%), squeezed by the fast-charging price war. On the expense side, administrative and other expenses fell 40.3% (share-based payments to zero, R&D scaled back) — the main driver of the narrower loss; that is, the improvement came more from "spending less" than from "earning more": absolute gross profit of only approx. RMB 2.8 million cannot cover approx. RMB 39 million of half-year administrative expenses. On the balance sheet: the FVTPL unlisted fund was dissolved and written to zero (fair-value loss of RMB 7.2 million in the period); 349,991 VisIC shares were transferred into FVOCI via distribution in kind (RMB 154.7 million at period-end, 28% of total assets); trade receivables rose RMB 15.4 million but were offset by a RMB 25.5 million increase in accounts payable — cash flow is sustained by occupying suppliers' funds. The company issues no formal guidance and has no sell-side consensus, so no "beat/miss" judgment is possible; against its own history, this is the first interim report since 2022 with "revenue acceleration + narrowing losses + narrowing operating cash outflow (-31.70 million → -13.93 million)" all moving in the same direction — but the contradiction of RMB 7.2 million in cash versus a half-year net outflow of approx. RMB 17.5 million remains unresolved.
Business model in brief: A heavy-asset IDM transition structure—LED bead manufacturing (packaging) is the legacy cash gross-profit source; revenue is entirely one-off product sales, no recurring revenue, no pricing power (FY2023 annual report self-described "implemented price reduction strategy… conducive to safeguarding sales of that product segment"; LED gross margin declined from 18.8% to 2.6% over four years before rebounding to 5.8% in 2026H1). The GaN business, via Shenzhen Jiahong (Xuzhou 6-inch epitaxy in mass production; 8-inch line targeting 2,000 wafers/month; planned full relocation to Chizhou with module packaging line), runs an "epitaxy—devices—packaging & testing—modules" full-chain narrative. Cumulative segment losses of ~RMB 297 million from FY2023–2026H1 (estimated)—a capital black hole alongside the core business.
Cash content of earnings test: Operating cash flow negative for four consecutive years (-23.2/-69.7/-28.9/-13.9 million); OCF and FCF ratios to net profit are meaningless under double-negative conditions, so look at absolute gaps: FCF gap FY2023 -131.2 million (peak of Xuzhou plant construction), FY2024 -82.7, FY2025 -73.9, 2026H1 -17.6 million—beyond book losses, the real cash bleed far exceeds what revenue scale could cover. Every rebound in cash balance came from rights issues/borrowings rather than operations (FY2025 announcement admitted "mainly due to… proceeds received from the rights issue"). Recurring earnings test: excluding one-off impairments, recurring losses for FY2023–FY2025 were -96.70 million/-113 million/-111 million, differing from attributable losses by less than 15%—i.e., the core losses are recurring, not impairment masking; the company disclosed no Non-GAAP adjustment framework (no way to check rigor), but FY2024 included RMB 35.3 million of share-based payments in administrative expenses, and share-based payments fell to zero in 2026H1—the large volatility of incentive expense is itself a source of earnings-quality noise.
Return on capital: FY2025 ROIC approximately -26% (NOPAT ≈ -RMB 134 million / invested capital ≈ RMB 515 million), far below any reasonable WACC—GaN investment has yet to generate any return; the "pseudo-growth" alarm is fully triggered. This is narrative-driven transformation, not validated capital allocation.
Capex quality: capex/depreciation FY2023 ~5.8 (plant construction period), FY2024 ~0.8 (investment halted), FY2025 ~2.0 (MOCVD/8-inch line restart)—impossible to distinguish maintenance from growth capex (no breakdown disclosed); combined with capacity figures (6-inch just in mass production, 8-inch dependent on two newly purchased MOCVD machines) and revenue scale (GaN annual revenue under RMB 30 million), all current capex is in substance "growth option" investment, whose return depends on order fulfillment after the Chizhou line starts production—unverified.
Earnings-quality red flags (with sources): ① Cash runway of ~2.5 months (2026 interim report Note 15); ② Operating cash flow negative for four consecutive years, survival dependent on equity financing and debt capitalization (FY2025 announcement MD&A); ③ Heavy share-based payment burden (FY2024 RMB 35.3 million = 46.9% of revenue; FY2025 RMB 33.1 million = 33.9% of revenue); ④ GaN capital injection carries a 6% simple-interest put-back right plus joint and several guarantees—economic substance close to off-balance-sheet contingent obligations akin to interest-bearing debt (2026-10-29 announcement).
Track record of words vs. deeds: partially delivered, favors grand narratives. ① FY2024 annual report promised "8-inch epitaxial wafers… expected to enter mass production in the first half of 2025" and "GaN chips… expected to pass reliability testing and launch in 2025"—FY2025 GaN revenue did rise to RMB 29.59 million, but plummeted to RMB 5.3 million in 2026H1, attributed to pricing disadvantage; the "2,000 wafers/month" 8-inch capacity figure was only raised in the 2026-10 announcement and depends on newly purchased equipment; ② 2023-09 Taizhou Huirong pledged a RMB 100 million capital injection—the second tranche of RMB 45 million defaulted after two extensions, terminated in 2025-01 with investors exonerated, and RMB 34 million impairment was borne by the listed company; ③ 2024-11 rights issue net proceeds of HK$87.80 million pledged for R&D and working capital—FY2025 annual report confirmed "fully utilized as at 31 December 2025," use consistent (delivered); ④ FY2023–FY2025 annual reports successively forecast "gradually entering harvest period in the foreseeable future" and "committed to becoming a full-chain GaN IDM enterprise"—the target group lost RMB 53.30 million in FY2025 and RMB 21.80 million in 2026H1, no harvest yet; new commitments shifted to plant relocation to Chizhou + listing application submission before 2031 (contractual). Overall verdict: acceptable record on use-of-proceeds compliance, poor record on business promise delivery, narrative goalposts continuously moved forward.
Shareholder friendliness: favors dilution over returns. FY2022–2026H1 zero dividends, zero buybacks (each period's announcements: "no dividend recommended" and "no purchase, sale or redemption of any listed securities"); total shares rose from 581.6 million at the start of 2022 to 1,171.9 million by 2026-10 (+101.5%), and to ~1,349 million after full CB conversion (a further +15.1%)—share capital doubled in four years entirely for debt repayment/acquisitions/incentives, with public shareholders bearing all dilution.
Risk signals: ① Auditor changed from BDO Hong Kong to RSM (Hong Kong) in FY2025, with no explanation in the announcement; ② 2021 share options (strike prices HK$7.50/1.40) lapsed entirely as the share price stayed below strike prices, replaced in 2024-12 by share awards with no performance hurdles (second tranche 67.57 million shares @0.57); ③ 2026-08-27: 148 million shares (12.53%) transferred into Citibank custody—commonly seen preceding pledges or disposals (attribution and purpose to be disclosed); ④ No disclosed anomalies at the key-person level, but the lapse-restart cycle of incentive instruments weakens management-shareholder interest alignment.
| Segment | FY2023 | FY2024 | FY2025 | 2026H1 | Business logic in one line |
|---|---|---|---|---|---|
| LED product revenue (RMB million) | 85.6 | 73.9 | 68.2 | 46.3 | Bead packaging; cash gross-profit source via price cuts to hold share |
| — Share / gross margin | 96.7% / 13.7% | 98.2% / 10.6% | 69.7% / 2.6% | 89.7% / 5.8% | No pricing power; weak gross-profit elasticity in cost-push price cycles |
| GaN and other semiconductor revenue (RMB million) | 3.0 | 1.4 | 29.6 | 5.3 | Epitaxy/devices + fast-charging applications; hit by price war post-ramp |
| — Share / gross margin | 3.3% / -109.1% | 1.8% / -3.1% | 30.3% / 8.9% | 10.3% / 1.8% | Segment results FY2023–2026H1: -96.90/-114.70/-64.70/-23.10 million |
| Shenzhen Jiahong (GaN vehicle; group stake 73.28%→68.21%) | — | Revenue 1.36 million | Revenue 29.59 million | Revenue 5.66 million | Net assets RMB 167 million at 2026-06-30; FY2025 loss RMB 53.30 million, 2026H1 loss RMB 21.80 million |
Profit-driving segment: In FY2025, GaN contributed ~60% of gross profit on 30.3% of revenue (RMB 2.65 million vs LED's RMB 1.77 million)—the gross-margin structure briefly inverted that year; but in 2026H1, GaN gross margin fell to 1.8% amid the price war, its gross-profit contribution dropped to ~3%, and LED again contributed ~90% of gross profit. The gross-margin gap reached 13.7 percentage points at its widest (FY2024: LED 10.6% vs GaN -3.1%); the root cause is that the two businesses are at different stages: LED is a margin-thin contract manufacturer in a mature red ocean, while GaN is in scale-diseconomies during ramp-up—unit costs won't fall (low utilization) while prices are pinned down by major players. GaN segment losses cumulated to ~RMB 300 million over four years, the absolute main driver of group losses; the violent swing from "ramp-up to stall" (FY2025 +2,076% → 2026H1 -34.8%) indicates an extremely thin order book with no stable customer base.
Accounting red flags (pattern / severity / original-text evidence):
Cross-period consistency: ① GaN segment revenue 2.95→1.36→29.59→5.30 million (half-year), wild swings with inconsistent management explanations (FY2025: "increase in mass production and volume shipments"; 2026H1: "at a competitive disadvantage in pricing versus large GaN manufacturers")—inconsistent; ② Blended gross margin 18.8%→9.6%→10.3%→4.5%→5.4%, management attribution direction coherent (price-cut strategy→falling ASPs + gold-wire costs)—consistent; ③ Period-end cash 49.3→8.8→14.6→7.2 million, each rebound from rights issues/borrowings—consistent (and self-corroborating financing dependence); ④ FY2023 operating cash flow figure restated—company did not explain; ⑤ Over-1-year receivables unchanged for four years—company did not explain.
Current market data (2026-11-06 close): Share price HK$0.196; total shares 1,171,854,481; market cap HK$229.68 million (at the 1st percentile of 5 years, 2nd percentile of 3 years). P/B ~0.46 (0% 1-year / 15% 3-year / 9% 5-year percentiles, computed from historical prices; net assets per share HK$0.4248); PS(TTM) ~1.68x (TTM revenue RMB 116.3 million); PE(TTM) -2.26x, forward PE not applicable (consecutive losses; this report forecasts losses for the next two years)—P/B is the only valid multiple; percentile data for reference only (P/E percentiles mechanically distorted during loss periods). Liquidity: 30-day average daily turnover ~HK$366,000 (~0.16% of market cap); single-day turnover on 2026-11-06 only ~HK$58,000, many days below HK$100,000—entry/exit impact costs could swallow double-digit percentage returns; any "fair value" beyond a small position is theoretical.
Peer comparison (as of 2026-11-06):
| Company | Market cap | P/B | PS(TTM) | Revenue growth | Key difference vs. HGG |
|---|---|---|---|---|---|
| HGG (Hogg Optical) 06908.HK | HK$230 million | 0.46 | 1.7 | 2026H1 +55.9% | Subject; GaN revenue is 0.6% of Innoscience's |
| Innoscence 02577.HK | HK$23.72 billion | 5.32 | 13.5 | 2026H1 +50.6% | World's No.1 in power GaN (31% share), 8-inch mass production, NVIDIA 800VDC supplier |
| Sanan Optoelectronics 600703.SH | — | 1.32 | — | 2026Q1-3 -27.3% | Global LED chip capacity leader + compound semiconductor platform; its 1.32x P/B can be viewed as a market-pricing ceiling reference for LED manufacturing assets |
| Navitas NVTS.US | ~US$4.6 billion (as of 2026-05) | — | >100 (sentiment reference) | 2025 -44.9% | Extreme narrative sample tied to NVIDIA; no comparability with HGG, shown only for sector sentiment range |
What the market has already priced in: HK$0.196 = a 46% discount to HK$0.42 net assets per share; on the RMB 1.158 billion post-money valuation the Chizhou state capital set for Jiahong, the market credits only 24.7% (68.21% stake worth ~HK$930 million vs market cap HK$230 million); even counting VisIC at book HK$182 million, the market prices "LED + Jiahong operating business − net liabilities" at ~HK$0.04/share, essentially zero. In one sentence: the current price assumes "continuous dilution + related-party transfers + parent cash exhaustion" will grind operating equity value to zero, while reality shows accelerating revenue, narrowing losses, and state capital entering with a 6% floor—the discount has fundamental grounds (RMB 400 million of free cash flow burned over four years), but unwinding the extreme pricing hinges on the single event of the capital injection closing. The counter-evidence must also be presented: in the 8 trading days after the Chizhou announcement (2026-10-29), the share price fell from a 10-day average of 0.207 to 0.196 (near the 52-week low of 0.19)—"the state-capital anchor being validated" has so far only counterexamples, no supporting cases.
Three-layer value: Asset value (floor) ~HK$0.14/share (range 0.10–0.19: VisIC at 40–55% discount + Jiahong book at 45–60% + LED book at 25–40% − net debt; independent references: Sanan's 1.32x P/B as LED asset ceiling, Innoscience's 5.32x P/B and Chizhou's 6.9x book as GaN premium references); EPV at zero growth is negative (system-computed at FCFE -HK$0.029/share ÷ 17% cost of equity ≈ -HK$0.17/share)—the current business's sustainable cash flow is negative; the market has paid nothing for profitability. The gap between current price and the asset-floor midpoint is ~HK$0.06/share (~29% of current price), the option premium paid for "Chizhou line + GaN volume + VisIC monetization." Note: when EPV is negative, the "growth option share" metric is distorted; the valid measure is "current price − asset floor ≈ 29%." The current price is mainly supported by the asset layer; the earnings layer contributes negatively.
Three scenarios and odds (12 months, HK$/share; probabilities are this report's judgment):
| Scenario | Probability | Fair range | vs. current | Key swing factors |
|---|---|---|---|---|
| Bear | 0.35 | 0.08–0.13 (midpoint 0.105) | -59% ~ -34% (midpoint -46%) | Injection terminated / conditions fail / put-back triggered → deep-discount refinancing or trading-halt restructuring; VisIC impaired 30–50%, cutting net assets per share by HK$0.07–0.10; extreme liquidation reference 0.03–0.07 |
| Base | 0.48 | 0.20–0.30 (midpoint 0.25) | +2% ~ +53% (midpoint +28%) | Injection approved + first RMB 40 million received + Chizhou progressing; refinancing at HK$0.20–0.26 to plug parent gap; post-dilution (~1,349 million shares) net assets per share ~HK$0.40 × 0.5–0.7x fair P/B (anchored to own 3-year median 0.82x, further discounted for governance/liquidity, independent of current price), SOTP cross-check crediting 15–25% of Chizhou's implied valuation |
| Bull | 0.17 | 0.50–0.65 (midpoint 0.575) | +155% ~ +232% | GaN orders land + VisIC valuation event (each +20–30% in next funding round → net assets +RMB 31–46 million) + sector mapping (mean-reversion elasticity toward Innoscience's 5.32x P/B) |
Probability-weighted expectation ~HK$0.25 (~+30% vs current price)—the positive expectation is mainly driven by the 17%-probability tail scenario; the base case offers only ~+28% vs current price, and the current price hugs the bottom of the base-case range (+2%). External anchor: three rounds of searches confirmed no institution has published a target price/rating/earnings forecast for 06908; no comparable external forecasts on either the bear or bull side—the three scenarios are a self-built framework—falsifiability rests on observable events such as EGM completion and turnover changes, not external pricing discipline.
In-house earnings forecast (performance reconciliation anchor):
| Period | Revenue (RMB million) | Net profit attributable (RMB million) | Key drivers |
|---|---|---|---|
| FY2026E | 99–108 | -65 ~ -75 | LED full-year 89–92 (H2 YoY +15–25%), GaN 10–13; low-single-digit gross margin; H2 attributable -30 ~ -40 |
| FY2027E | 110–135 | -45 ~ -65 | Chizhou packaging line small-batch in H2 + Xuzhou ramp (GaN 22–37); interest expense declines after injection lands; assumes no large VisIC fair-value gains/losses |
No formal management guidance (against contractual milestones: RMB 20 million of capital contribution within 2027, relocation completed before 2026-06-30); no sell-side consensus to compare against.
Conclusion: Valuation reasonably low—poor quality coexists with cheap price. Target price range HK$0.20–0.30 (base-case fair value), safety margin ~+2% (base-case floor 0.20 vs current price 0.196)—the "cheapness" mainly reflects an asset discount, not an earnings discount, and its realization requires two external conditions: injection closing + market liquidity returning. Position implications: core/fundamental portfolio weight 0%, speculative satellite position capped at ~1% (the liquidity trap renders any stop-loss discipline effectively meaningless).
Industry Size. The market the Company actually operates in is GaN-on-Si power semiconductors, while retaining an SMD LED lamp bead packaging business. The power GaN device market (per Yole's Power GaN 2025/2026): approximately USD 355 million in 2024 → approximately USD 588 million in 2025 (+63% YoY, cross-validated by both editions) → approximately USD 3.0 billion by 2030 (2025 edition) / approximately USD 3.5 billion by 2031 (2026 edition), implying a CAGR of roughly 42% for 2024–2030 and roughly 35% for 2025–2031; TrendForce pegs the 2025–2030 CAGR at roughly 44%. By downstream segment (2030–2031, Yole): consumer/mobile fast charging remains the base (share >50%, approximately USD 1.7 billion by 2031); the fastest-growing segments are telecom & infrastructure (AI data center power, 45% CAGR, reaching USD 750 million by 2031) and automotive (OBC/48V, 57% CAGR, exceeding USD 155 million by 2026). On the LED side: per TrendForce, the global LED lighting market was worth USD 53.57 billion in 2025, -4.4% YoY, in the final stages of consolidation within a mature declining phase, with some product prices bottoming out and rebounding in early 2026 (Sanan's LED epitaxial chip revenue -2.91% in 2025 and recovering +11.81% in 2026H1 confirms a bottoming), with low single-digit overall growth over the next 3–5 years driven by Mini/Micro LED structural upgrades.
Quantified Chain of the Demand Inflection (industry-level quantified, no company-level positioning). The AI data center power architecture transition is GaN's second growth curve: NVIDIA released its 800V HVDC architecture in May 2025 and announced its supplier list in July (TI, Navitas, Infineon, Innoscience, onsemi, etc., with Innoscience the only Chinese company), with per-rack power leaping from the hundreds-of-kilowatts range to the megawatt range, and GaN's applicable threshold jumping from <100W fast charging to ≥3kW server power supplies (Navitas has already released a 12kW reference design); the timeline is architecture release in 2025 → sampling/validation in 2026 → first commercial deployment in 2027 (Yole) → 45% CAGR scale-up for the segment through 2027–2031. The company-level evidence chain is broken: Hongguang is not on the supplier list; 2026H1 GaN revenue was RMB 5.3 million, -34.9% YoY, with no quantified positioning for this inflection—the industry beta is being captured by leaders such as Innoscience (2025 AI/data center revenue RMB 63 million, +50.2%) and Navitas (high-power segment already its main revenue source); Hongguang's exposure is indirect, via its approximately 18% equity stake in VisIC (whose 800V product line extends to data center power).
Value Chain and Value Distribution. The GaN value chain: substrates (mainstream is standard silicon wafers—ample supply, limited bargaining power; vertical GaN uses free-standing substrates dominated by Sumitomo Electric/Mitsubishi Chemical) → epitaxy (MOCVD equipment: Aixtron, AMEC, NAURA; the epitaxy step carries high technical barriers) → device manufacturing (dual-track IDM and foundry: IDMs such as Infineon, Innoscience, TI, and ST dominate; on the foundry side, TSMC exits GaN by 2027, with capacity and technology licensing shifting to GlobalFoundries/Vanguard/Powa Technology—Yole judges the industry's center of gravity tilting toward IDMs) → devices/modules → end market (fast-charging ODMs, AI server power supplies, automotive Tier 1s). Gross margin accrues to scaled IDM players (Innoscience's gross margin has recovered from -19.5% to 11.6% and is rising each period); Hongguang is nominally an IDM (epitaxy—devices—packaging & testing—modules) but in reality sits at the weakest rung of the midstream: the Xuzhou 6-inch epitaxy line only completed equipment commissioning in early 2026, and the 8-inch line depends on the two newly purchased MOCVD reactors in this transaction (approximately RMB 29 million) for development; the Company itself admits it is "at a competitive disadvantage in pricing versus large GaN manufacturers"—no bargaining power upstream (equipment/materials), a price taker downstream (fast-charging ODMs), with a 2026H1 GaN gross margin of only 1.8%. In the LED value chain, Hongguang is a midstream lamp bead packager, squeezed from both directions by upstream chip/lead-frame price increases and weak downstream consumer demand. One structural backdrop on the raw materials side: China accounts for over 90% of global gallium production, and export controls on gallium-related items since August 2023 (principally unavailable for export to the US since December 2024) give Chinese GaN manufacturers a high degree of raw material self-sufficiency—neutral-to-protective for domestic production line players like Hongguang.
Supply-Demand and Competitive Landscape. Demand drivers: consumer fast-charging penetration stabilizing (the base) + AI data centers (first commercial deployment 2027) + NEV OBC/48V (China NEV wholesale volume in November 2025: 1.823 million units, +20.6% YoY). Supply side: capacity expansion far outstrips demand growth—Innoscience's 8-inch capacity is 20,000 wafers/month (2025 annual report) with plans to expand to 70,000 wafers/month by 2029 (Suzhou Phase I investment approximately RMB 8 billion); Infineon sampled 300mm GaN in 2025Q4 (world's first 12-inch); TI plans to quadruple internal GaN capacity once Aizu + Dallas come online; GlobalFoundries/Vanguard/Powa Technology absorb TSMC's transferred capacity; domestic newcomers include Xinwei (annual capacity 60,000 wafers) and Gejing (RMB 2.5 billion, 50,000 8-inch wafers/year). The competitive landscape is highly concentrated: 2024 CR5 approximately 86.9% (Innoscience 30%, Navitas 17%, PI 15.2%, EPC 13.5%, Infineon 11.2%); in 2025 the top three are Innoscience 31%, Infineon 16% (leaping from fifth to second), PI 14%, CR3 approximately 61%—Hongguang is not on the list. Competitive intensity: homogeneous price wars in low-voltage fast charging (Navitas abandoned the mobile fast-charging core market due to price competition, 2025 revenue -44.9%; Infineon uses its 300mm cost advantage to compete from a higher plane; Innoscience crushes smaller players with capacity + cost), while the automotive/high-voltage and AI data center segments remain in the design-in phase through 2027. Entry barriers: 8-inch process yield (Innoscience 95%, unit cost approximately -30% versus 6-inch), automotive qualification (AEC-Q101), dense patent litigation (Infineon's Section 337 case against Innoscience: the ITC issued a final ruling in May 2026 finding infringement and an import ban on related products, while Innoscience won a separate case allowing continued US sales), capital thresholds (Innoscience Phase I RMB 8 billion versus Hongguang Jiahong's cumulative external capital injections of RMB 180 million), and customer onboarding cycles (2–3 years for data centers). Substitution threats run both ways: squeezed at the high end by SiC (EV main drives) and suppressed at low/medium voltage by silicon superjunction MOSFET costs.
Cycles and Regulation. Power GaN is at the late introduction stage → early scale-up phase (early growth stage of the lifecycle, early upcycle). Leading indicators: the commercialization timing of NVIDIA's 800VDC supply chain (2027), Innoscience's data center revenue and gross margin, Infineon's 300mm mass-production schedule, and GaN average selling prices. LED is at the late-mature consolidation stage; leading indicators: Sanan's LED chip gross margin (2025H1 26.03%, +6.68pct) and the durability of price increase letters. Regulation: China's "14th Five-Year Plan" lists third-generation semiconductor industrialization as a priority, and Guangdong's October 2024 Photonic Chip Action Plan (2024–2030) provides subsidies—positive for the domestic GaN value chain; the US Entity List (140 Chinese semiconductor entities added in December 2024) + equipment controls + the ITC Section 337 ban raise the overseas expansion threshold for Chinese GaN makers—a substantive barrier for Hongguang (mainly domestic sales, technically weak) going overseas, with a neutral impact on its home market.
Peer Benchmarking Table (supporting the "two orders of magnitude scale gap" judgment):
| Company | Revenue Scale | Revenue Growth | Gross Margin | ROE | Market Share/Ranking |
|---|---|---|---|---|---|
| Innoscience 02577.HK | FY2025 RMB 1.213 billion; 2026H1 RMB 834 million | FY2025 +46.4%; 2026H1 +50.6% | 2026H1 11.6% (-19.5% → improving each period) | Negative (FY2025 net loss RMB 841 million) | Global No. 1 in power GaN (31%) |
| Navitas NVTS.US | FY2025 USD 45.9 million | FY2025 -44.9% | Non-GAAP approximately 39% | Negative | 17% in 2024 (No. 2) → fell out of the top three in 2025 |
| Power Integrations POWI.US | FY2025 USD 443.5 million (PowiGaN >10%) | FY2025 +6% (PowiGaN +40%+) | Approximately 53–54% | Positive (profitable) | 14% in 2025 (No. 3) |
| Sanan Optoelectronics 600703.SH | FY2025 RMB 17.95 billion (LED epitaxial chips RMB 5.86 billion) | FY2025 +11.4% | 2024 11.9% | Negative (first loss in 2025) | Global LED chip capacity leader |
| Hongguang Semiconductor 06908.HK | FY2025 RMB 98 million (GaN segment RMB 30 million) | FY2025 +29.9%; 2026H1 +55.9% | FY2025 4.5%; 2026H1 5.4% | Deeply negative (ROIC approximately -26%) | Not on Yole's list (approximately 0.2%) |
Company Industry Positioning: a niche/early follower whose catch-up momentum has actually regressed over the past year. Hongguang's GaN revenue (2026H1 RMB 5.3 million) is roughly 0.6% of Innoscience's over the same period and roughly 0.2% of the global market (extrapolated on a half-year basis), with market share trending down rather than up. Moat assessment: IDM production line—the Xuzhou 6-inch line has just completed commissioning and the 8-inch line relies on newly purchased equipment; the capital expenditure intensity gap versus peers is vast (Innoscience Suzhou Phase I RMB 8 billion, Gejing/Bofang Jiaxin RMB 2.5 billion each versus Hongguang Jiahong's two rounds of external capital injections totaling RMB 180 million—about 2.3% of Innoscience's Phase I, enough only to sustain a 6-inch epitaxy + pilot-scale packaging & testing footprint); the Harvest-affiliated strategic investor (RMB 100 million injection in 2023) and Chizhou state-owned capital (RMB 80 million this time) are financial and local-government endorsements, not industrial order validation; the most substantive chip in its technology linkage is the approximately 18% equity stake in VisIC and a small number of utility model patents. The core LED business (2026H1 revenue RMB 46.32 million, gross margin 5.8%) is a low-price red ocean at the end of consolidation—a cash cow, not a moat. Hongguang is currently absent from the list of those capturing industry upside; it is "a bystander to the sector's beta + a holder of the VisIC option + a recipient of local government industrial investment promotion."
Overall Assessment: Neutral (confidence 0.40), horizon 6–12 months. The deep asset discount (P/B 0.46, Jiahong's implied valuation at 4x the market cap—a inversion) is real, but the path to closing the discount is event-driven (Chizhou capital injection closing → market ratification), not fundamentals-driven (narrowing losses are insufficient to support valuation); meanwhile, the parent company's 2.5-month cash runway, 15.1% dilution in transit, family dual-track pricing, and the 6% put-contingent liability (principal totaling RMB 180 million, roughly half of net assets) continuously erode per-share value. The odds skew upward (probability-weighted approximately +30%) but the payoff lies in the tail, and the base case implies only approximately +28% from the current price—we do not recommend chasing; holders should treat HKD 0.20/0.30 as observation marks for re-rating/exit; any participation should be treated as a lottery-ticket position (capped at approximately 1%), with acceptance that stop-loss discipline fails under a liquidity trap.
Risks and Catalysts (next 6–12 months): Verification path in chronological order—circular dispatch (≤2026-11-26) → Chizhou capital injection EGM (expected 2026-12) and receipt of the first RMB 40 million tranche → note replacement EGM and completion (≤2027-02-28) → FY2026 annual report (around 2027-03, watch audit opinion and going-concern language) → MOCVD purchase/relocation/second capital injection (≤2027-06-30) → Jiahong's self-funded RMB 20 million contribution (≤2027-12-31, breach triggers the put). Falsification signals: EGM rejection or termination of the capital injection, a discounted placement below HKD 0.15, an annual report with "material uncertainty over going concern" or a qualified opinion, a VisIC valuation markdown exceeding 30%, or full-year GaN revenue below RMB 10 million. Also to track: the attribution and disposal of Citigroup's 148 million custodied shares, supply digestion during the initial trading of the consideration shares, and disclosures of changes in the Zhan family's interests.
Key Data and Basis Notes: Financial data are sourced from the Company's results announcements/interim reports (RMB, fiscal year ending 12-31); market data are frozen at the 2026-11-06 close anchor; exchange rate: RMB 1 = HKD 1.176071 (2026-11-07). Industry data sources: Yole Group's Power GaN 2025/2026 (as republished by compoundsemiconductor/cnyes), TrendForce, and the Company's 2026 interim report. All forward-looking judgments in this report are based on public information; there is a material gap between the actual tradability of a micro-cap stock and this report's theoretical valuation.